Company / Return on Equity (ROE)
AVADEL PHARMACEUTICALS PLC Return on Equity (ROE) History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-66.1%
FY2024
5-year range
-182.7% / 4.3%
FY2020-FY2024
Trend
+63.8%
vs FY2023
Sector context
#152 of 190
Health Care
What the data says
AVADEL PHARMACEUTICALS PLC reports negative total equity of -66.1% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-66.1% in FY2024 with a 3-year CAGR of +32.7%.
Improved from -98.8% to -66.1% over the past 3 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +32.7pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 190This company -66.1% Sector average -50.3%
▼
-31.4% below sector average
Key checks
Key Insights
- In FY2024, return on equity (roe) increased 63.8% year-over-year.
- Currently 15.8pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2017.
- Lowest return on equity (roe) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -66.1% | +63.8% |
| FY2023 | -182.7% | - |
| FY2022 | - | - |
| FY2021 | -98.8% | -2382.4% |
| FY2020 | 4.3% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | 79.8% | +181.3% |
| FY2016 | -98.1% | -262.3% |
| FY2015 | 60.5% | +117.7% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026